Anti-Ganglioside GD2 Reference Antibody (Lorukafusp Alfa, RUO) (YP115026)

Name: Anti-Ganglioside GD2 Reference Antibody (Lorukafusp Alfa, RUO)
Brand: abinScience
SKU: YP115026
Price: 176 USD
Availability: InStock

Даташит Поделиться продуктом Копировать информацию

Цена(USD):

Спецификация:

100ug
1mg
5mg
10mg
25mg
50mg
100mg

Количество:

Свяжитесь с нами

Обзор
Изображения
Ссылки
Даташит
SDS

Обзор

Каталожный номер	YP115026
Реактивность видов	General
Применения	ELISA, Bioactivity: FACS, Functional assay, Research in vivo
Хозяинский вид	Chimeric
Клоональность	Monoclonal
Изотип	IgG1-kappa
ID клона	Lorukafusp Alfa
Биологическая активность	Ganglioside GD2 is associated with tumor development and malignant phenotypes, and its mechanism of action involves enhancing cell proliferation, motility, migration, adhesion and invasion, with specific effects depending on tumor type [1].
Система экспрессии	Mammalian cells
Цель	Ganglioside GD2
Уровень эндотоксинов	< 10 EU/mg
Чистота	>95% purity as determined by SDS-PAGE.
Очистка	Protein A/G purified from cell culture supernatant.
Номер доступа	CAS: 65988-71-8
Форма	Liquid
Буфер хранения	0.01M PBS pH 7.4 Пожалуйста, обратитесь к конкретной информации о буфере в печатной версии даташита или в индивидуальном сертификате качества (COA) для партии.
Устойчивость и хранение	Use a manual defrost freezer and avoid repeated freeze thaw cycles. Store at 2 to 8°C for frequent use. Store at -20 to -80°C for twelve months from the date of receipt.
Альтернативные названия	14.18 mAb, 14.18-IL-2, EMD273063, EMD 273063, EMD-273063, Hu14.18-IL-2, Hu14.18-IL2, anti-GD2 fused to IL2, hu14.18-IL2, hu14.18-Interleukin-2 fusion protein, CAS: 2131168-99-3
Фон	Lorukafusp alfa (14.18 mAb; hu14.18-IL2) is an immunocytokine consisting of the humanized 14.18 anti-GD2 mAb linked to IL210. Lorukafusp alfa has activity mediated by activation of antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity via the binding of hu14.18-IL2 to GD2 on the tumor cell surface, followed by binding to Fc receptors on effector cells along with activation of NK and T cells via IL2 receptor binding. Lorukafusp alfa has anti-tumor activity. • Ganglioside GD2: a novel therapeutic target in triple-negative breast cancer., PMID:34596246 • GD2 is a Crucial Ganglioside in the Signal Modulation and Application as a Target of Cancer Therapeutics., PMID:39921214 • Preclinical Development of CAR T Cells with Antigen-Inducible IL18 Enforcement to Treat GD2-Positive Solid Cancers., PMID:38593230 • Ganglioside GD2 Contributes to a Stem-Like Phenotype in Intrahepatic Cholangiocarcinoma., PMID:39726234 • Preclinical assessment of the efficacy and specificity of GD2-B7H3 SynNotch CAR-T in metastatic neuroblastoma., PMID:33479234 • Ganglioside GD2 Enhances the Malignant Phenotypes of Melanoma Cells by Cooperating with Integrins., PMID:35008849 • RNA Sequencing-Based Identification of Ganglioside GD2-Positive Cancer Phenotype., PMID:32486168 • Potent antitumor efficacy of anti-GD2 CAR T cells in H3-K27M⁺ diffuse midline gliomas., PMID:29662203 • Anti-GD2 antibody with GM-CSF, interleukin-2, and isotretinoin for neuroblastoma., PMID:20879881
Ссылки	1. Nazha B, et al. Disialoganglioside GD2 Expression in Solid Tumors and Role as a Target for Cancer Therapy. Front Oncol. 2020;10:1000. Published 2020 Jul 7. [YP115026] 2. Erber R, et al. Variable Expression of the Disialoganglioside GD2 in Breast Cancer Molecular Subtypes. Cancers (Basel). 2021;13(21):5577. Published 2021 Nov 8. [YP115026]
Примечание	For research use only. Not suitable for clinical or therapeutic use.